312 related articles for article (PubMed ID: 26493010)
1. Activity of botulinum toxin type A in cranial dura: implications for treatment of migraine and other headaches.
Lacković Z; Filipović B; Matak I; Helyes Z
Br J Pharmacol; 2016 Jan; 173(2):279-91. PubMed ID: 26493010
[TBL] [Abstract][Full Text] [Related]
2. Role of central versus peripheral opioid system in antinociceptive and anti-inflammatory effect of botulinum toxin type A in trigeminal region.
Drinovac Vlah V; Filipović B; Bach-Rojecky L; Lacković Z
Eur J Pain; 2018 Mar; 22(3):583-591. PubMed ID: 29134730
[TBL] [Abstract][Full Text] [Related]
3. Central action of peripherally applied botulinum toxin type A on pain and dural protein extravasation in rat model of trigeminal neuropathy.
Filipović B; Matak I; Bach-Rojecky L; Lacković Z
PLoS One; 2012; 7(1):e29803. PubMed ID: 22238656
[TBL] [Abstract][Full Text] [Related]
4. The impact of the migraine treatment onabotulinumtoxinA on inflammatory and pain responses: Insights from an animal model.
Reducha PV; Bömers JP; Edvinsson L; Haanes KA
Headache; 2024 Jun; 64(6):652-662. PubMed ID: 38700141
[TBL] [Abstract][Full Text] [Related]
5. Dural administration of inflammatory soup or Complete Freund's Adjuvant induces activation and inflammatory response in the rat trigeminal ganglion.
Lukács M; Haanes KA; Majláth Z; Tajti J; Vécsei L; Warfvinge K; Edvinsson L
J Headache Pain; 2015; 16():564. PubMed ID: 26329487
[TBL] [Abstract][Full Text] [Related]
6. Functional immunohistochemistry of neuropeptides and nitric oxide synthase in the nerve fibers of the supratentorial dura mater in an experimental migraine model.
Knyihár-Csillik E; Tajti J; Chadaide Z; Csillik B; Vécsei L
Microsc Res Tech; 2001 May; 53(3):193-211. PubMed ID: 11301495
[TBL] [Abstract][Full Text] [Related]
7. Effect of a serotonin agonist (sumatriptan) on the peptidergic innervation of the rat cerebral dura mater and on the expression of c-fos in the caudal trigeminal nucleus in an experimental migraine model.
Knyihár-Csillik E; Tajti J; Samsam M; Sáry G; Slezák S; Vécsei L
J Neurosci Res; 1997 Jun; 48(5):449-64. PubMed ID: 9185668
[TBL] [Abstract][Full Text] [Related]
8. Trigeminal activation patterns evoked by chemical stimulation of the dura mater in rats.
Laborc KF; Spekker E; Bohár Z; Szűcs M; Nagy-Grócz G; Fejes-Szabó A; Vécsei L; Párdutz Á
J Headache Pain; 2020 Aug; 21(1):101. PubMed ID: 32799798
[TBL] [Abstract][Full Text] [Related]
9. Sonographic guide for botulinum toxin injections for chronic migraine headache: EURO-MUSCULUS/USPRM approach.
Kara M; Ricci V; Pirri C; Sekizkardeş M; Cocco G; Stecco C; Kaymak B; Özçakar L
Clin Neurol Neurosurg; 2023 Sep; 232():107883. PubMed ID: 37467578
[TBL] [Abstract][Full Text] [Related]
10. Botulinum toxin type A selectivity for certain types of pain is associated with capsaicin-sensitive neurons.
Matak I; Rossetto O; Lacković Z
Pain; 2014 Aug; 155(8):1516-1526. PubMed ID: 24793910
[TBL] [Abstract][Full Text] [Related]
11. Dural Calcitonin Gene-Related Peptide Produces Female-Specific Responses in Rodent Migraine Models.
Avona A; Burgos-Vega C; Burton MD; Akopian AN; Price TJ; Dussor G
J Neurosci; 2019 May; 39(22):4323-4331. PubMed ID: 30962278
[TBL] [Abstract][Full Text] [Related]
12. Dural neurogenic inflammation induced by neuropathic pain is specific to cranial region.
Filipović B; Matak I; Lacković Z
J Neural Transm (Vienna); 2014 May; 121(5):555-63. PubMed ID: 24366531
[TBL] [Abstract][Full Text] [Related]
13. Modulation of inflammatory mediators in the trigeminal ganglion by botulinum neurotoxin type A: an organ culture study.
Edvinsson J; Warfvinge K; Edvinsson L
J Headache Pain; 2015; 16():555. PubMed ID: 26245187
[TBL] [Abstract][Full Text] [Related]
14. Botulinum toxin type a antinociceptive activity in trigeminal regions involves central transcytosis.
Nemanić D; Mustapić M; Matak I; Bach-Rojecky L
Eur J Pharmacol; 2024 Jan; 963():176279. PubMed ID: 38123005
[TBL] [Abstract][Full Text] [Related]
15. [Botulinum neurotoxin--a therapy in migraine].
Tajti J; Szok D; Tuka B; Csáti A; Kuris A; Majláth Z; Lukács M; Vécsei L
Ideggyogy Sz; 2012 Mar; 65(3-4):77-82. PubMed ID: 23136725
[TBL] [Abstract][Full Text] [Related]
16. The trigemino-vascular system and migraine.
Buzzi MG; Moskowitz MA
Pathol Biol (Paris); 1992 Apr; 40(4):313-7. PubMed ID: 1379707
[TBL] [Abstract][Full Text] [Related]
17. Experimental inflammation following dural application of complete Freund's adjuvant or inflammatory soup does not alter brain and trigeminal microvascular passage.
Lundblad C; Haanes KA; Grände G; Edvinsson L
J Headache Pain; 2015; 16():91. PubMed ID: 26512021
[TBL] [Abstract][Full Text] [Related]
18. Botulinum toxin: A review of the mode of action in migraine.
Do TP; Hvedstrup J; Schytz HW
Acta Neurol Scand; 2018 May; 137(5):442-451. PubMed ID: 29405250
[TBL] [Abstract][Full Text] [Related]
19. Extracranial injections of botulinum neurotoxin type A inhibit intracranial meningeal nociceptors' responses to stimulation of TRPV1 and TRPA1 channels: Are we getting closer to solving this puzzle?
Zhang X; Strassman AM; Novack V; Brin MF; Burstein R
Cephalalgia; 2016 Aug; 36(9):875-86. PubMed ID: 26984967
[TBL] [Abstract][Full Text] [Related]
20. Evidence for central antispastic effect of botulinum toxin type A.
Matak I
Br J Pharmacol; 2020 Jan; 177(1):65-76. PubMed ID: 31444910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
